NR1I2 antibody (N-Term)
Quick Overview for NR1I2 antibody (N-Term) (ABIN2774988)
Target
See all NR1I2 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- N-Term
-
Sequence
- KKEMIMSDEA VEERRALIKR KKSERTGTQP LGVQGLTEEQ RMMIRELMDA
-
Predicted Reactivity
- Human: 100%
-
Characteristics
- This is a rabbit polyclonal antibody against NR1I2. It was validated on Western Blot using a cell lysate as a positive control.
-
Purification
- Affinity Purified
-
Immunogen
- The immunogen is a synthetic peptide directed towards the N terminal region of human NR1I2
-
-
-
-
Application Notes
- Optimal working dilutions should be determined experimentally by the investigator.
-
Comment
-
Antigen size: 434 AA
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- Lot specific
-
Buffer
- Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freeze-thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.
-
-
-
: "Induced CYP3A4 expression in confluent Huh7 hepatoma cells as a result of decreased cell proliferation and subsequent pregnane X receptor activation." in: Molecular pharmacology, Vol. 83, Issue 3, pp. 659-70, (2013) (PubMed).
: "Chrysin ameliorates chemically induced colitis in the mouse through modulation of a PXR/NF-?B signaling pathway." in: The Journal of pharmacology and experimental therapeutics, Vol. 345, Issue 3, pp. 473-82, (2013) (PubMed).
-
: "Induced CYP3A4 expression in confluent Huh7 hepatoma cells as a result of decreased cell proliferation and subsequent pregnane X receptor activation." in: Molecular pharmacology, Vol. 83, Issue 3, pp. 659-70, (2013) (PubMed).
-
- NR1I2 (Nuclear Receptor Subfamily 1, Group I, Member 2 (NR1I2))
-
Alternative Name
- NR1I2
-
Background
-
NR1I2 belongs to the nuclear receptor superfamily, members of which are transcription factors characterized by a ligand-binding domain and a DNA-binding domain. NR1I2 contains a zinc finger domain.NR1I2 is a transcriptional regulator of the cytochrome P450 gene CYP3A4, binding to the response element of the CYP3A4 promoter as a heterodimer with the 9-cis retinoic acid receptor RXR. It is activated by a range of compounds that induce CYP3A4, including dexamethasone and rifampicin. NR1I2 belongs to the nuclear receptor superfamily, members of which are transcription factors characterized by a ligand-binding domain and a DNA-binding domain. This gene product belongs to the nuclear receptor superfamily, members of which are transcription factors characterized by a ligand-binding domain and a DNA-binding domain. The encoded protein is a transcriptional regulator of the cytochrome P450 gene CYP3A4, binding to the response element of the CYP3A4 promoter as a heterodimer with the 9-cis retinoic acid receptor RXR. It is activated by a range of compounds that induce CYP3A4, including dexamethasone and rifampicin. Several alternatively spliced transcripts encoding different isoforms, some of which use non-AUG (CUG) translation initiation codon, have been described for this gene. Additional transcript variants exist, however, they have not been fully characterized.
Alias Symbols: BXR, ONR1, PAR, PAR1, PAR2, PARq, PRR, PXR, SAR, SXR
Protein Interaction Partner: NCOA1, RPS6KB1, UBC, RBBP7, DDB1, UBR5, DYRK2, NCOR2, SDF4, NCOA3, TFAP2C, MAPK7, NFATC4, HSP90AA1, FGR, ATP6AP1, RXRA, RBCK1, NCOA2, SUMO1, SUMO2, SUMO3, NCOA6, SRC, RXRG, RXRB, CHMP1A, NUCB2, ACTN2, PPARGC1A, EIF3I, TADA3, NCOR1, PRMT1, NR1I2, PSMC5, PO
Protein Size: 434 -
Molecular Weight
- 50 kDa
-
Gene ID
- 8856
-
NCBI Accession
- NM_003889, NP_003880
-
UniProt
- O75469
-
Pathways
- Nuclear Receptor Transcription Pathway, Steroid Hormone Mediated Signaling Pathway
Target
-